Abstract
In solid tumors, neoplastic cells are surrounded by a specific microenvironment that integrates the extracellular matrix, lymphatic and blood vessels, and mesenchymal and immune cells, which together are known as the tumor microenvironment (TME). The TME governs many of the aggressive features of tumors, such as local invasion and metastasis. Additionally, new evidence indicates that the TME can trigger stem cell-like programs in cancer cells, forming cancer stem cells (CSC). Experimental and clinical studies suggest that CSCs are resistant to current common cancer therapies and are responsible for tumor recurrence. In this review, we will describe the TME by focusing on how matrix metalloproteinases (MMPs) and cyclooxygenase-2 (COX-2) induce stemness and sustain stem cell maintenance. This reprogramming toward a CSC phenotype may be critical in tumor cell responses to chemotherapy and relapse with more aggressive tumor clones. Therefore, therapeutic agents targeting MMPs and COX-2 in the tumor microenvironment may become important drugs to control the establishment of CSCs and in the overall prognosis of the disease.
Keywords: Cancer stem cells, cyclooxygenase-2, epithelial-mesenchymal transition, metalloproteinases, stemness, tumor microenvironment.
Anti-Cancer Agents in Medicinal Chemistry
Title:A Role for the Inflammatory Mediators Cox-2 and Metalloproteinases in Cancer Stemness
Volume: 15 Issue: 7
Author(s): G.K. Chimal-Ramírez, N.A. Espinoza-Sanchez and E.M. Fuentes-Panana
Affiliation:
Keywords: Cancer stem cells, cyclooxygenase-2, epithelial-mesenchymal transition, metalloproteinases, stemness, tumor microenvironment.
Abstract: In solid tumors, neoplastic cells are surrounded by a specific microenvironment that integrates the extracellular matrix, lymphatic and blood vessels, and mesenchymal and immune cells, which together are known as the tumor microenvironment (TME). The TME governs many of the aggressive features of tumors, such as local invasion and metastasis. Additionally, new evidence indicates that the TME can trigger stem cell-like programs in cancer cells, forming cancer stem cells (CSC). Experimental and clinical studies suggest that CSCs are resistant to current common cancer therapies and are responsible for tumor recurrence. In this review, we will describe the TME by focusing on how matrix metalloproteinases (MMPs) and cyclooxygenase-2 (COX-2) induce stemness and sustain stem cell maintenance. This reprogramming toward a CSC phenotype may be critical in tumor cell responses to chemotherapy and relapse with more aggressive tumor clones. Therefore, therapeutic agents targeting MMPs and COX-2 in the tumor microenvironment may become important drugs to control the establishment of CSCs and in the overall prognosis of the disease.
Export Options
About this article
Cite this article as:
Chimal-Ramírez G.K., Espinoza-Sanchez N.A. and Fuentes-Panana E.M., A Role for the Inflammatory Mediators Cox-2 and Metalloproteinases in Cancer Stemness, Anti-Cancer Agents in Medicinal Chemistry 2015; 15 (7) . https://dx.doi.org/10.2174/1871520615666150318100822
DOI https://dx.doi.org/10.2174/1871520615666150318100822 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Role of natural compounds as anti anti-cancer agents
Cancer is considered the leading cause of worldwide mortality, accounting for nearly 10 million deaths in 2022. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy remains an important approach in treatment o f several types of cancers, even though ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Insulin-like Growth Factor: Current Concepts and New Developments in Cancer Therapy
Recent Patents on Anti-Cancer Drug Discovery Revisiting the ABCs of Multidrug Resistance in Cancer Chemotherapy
Current Pharmaceutical Biotechnology Phage Display Applications for Molecular Imaging
Current Pharmaceutical Biotechnology New Perspectives in the Pharmacological Potential of Naringin in Medicine
Current Medicinal Chemistry Testosterone Deficiency Syndrome: Cellular and Molecular Mechanism of Action
Current Aging Science Withdrawal Notice: Characterization of Glyoxal Modified LDL: Role in the Generation of Circulating Autoantibodies in Type 2 Diabetes Mellitus and Coronary Artery Disease
Current Drug Targets Application of Nanotechnology in the Treatment and Diagnosis of Gastrointestinal Cancers: Review of Recent Patents
Recent Patents on Anti-Cancer Drug Discovery Serotonin and Cancer: What Is the Link?
Current Molecular Medicine Current Innovations in Laparoscopy
Current Women`s Health Reviews Enzyme / Abzyme Prodrug Activation Systems: Potential Use in Clinical Oncology
Current Pharmaceutical Design Quantitative Proteomics for Cancer Biomarker Discovery
Combinatorial Chemistry & High Throughput Screening A Link Between Chemical Structure and Biological Activity in Triterpenoids
Recent Patents on Anti-Cancer Drug Discovery Diethyldithiocarbamate complex with copper: the mechanism of action in cancer cells
Mini-Reviews in Medicinal Chemistry Investigation of in Vitro Release Dynamics of Cisplatin from Genipin Crosslinked Gelatin Nanocarriers
Drug Delivery Letters Purinergic Receptors and Pain
Current Pharmaceutical Design Biological Relevance of DNA Polymerase Beta and Translesion Synthesis Polymerases to Cancer and its Treatment
Current Molecular Pharmacology VEGF in Tumor Progression and Targeted Therapy
Current Cancer Drug Targets RNA-Mediated Therapeutics: From Gene Inactivation to Clinical Application
Current Topics in Medicinal Chemistry Lipid Metabolism and Mitochondria: Cross Talk in Cancer
Current Drug Targets Cellular Changes, Molecular Pathways and the Immune System Following Photodynamic Treatment
Current Medicinal Chemistry